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Abstract	
While transfusion of blood and blood products is instinctively linked to the provision of emergent care,
blood and blood products are also routinely used for the treatment of subacute and chronic conditions.
Despite the efforts of the World Health Organization and others, developing countries are faced with a
three-part problem when it comes to access to and delivery of transfusions: insufficient supply, excessive
demand, and inadequate quality of available supply. Developing countries rely heavily on replacement
and remunerated donors rather than voluntary nonremunerated donors due to concerns regarding
donation- and transfusion-transmitted infection as well as local and cultural beliefs. While increased
awareness of HIV and improved testing techniques have jointly reduced infection-related apprehensions
and improved the quality of available blood and blood products, continued efforts are warranted to bolster
testing for other bloodborne pathogens. Similarly, although prevalence rates of anemia are high in some
areas of the world, success in adequate widespread management of these conditions has been limited.
One of the keys to expanding access to high-quality blood and blood products is thus to improve medical
management of conditions that would otherwise require transfusion. Through a three-pronged approach
to address quantity, quality, and demand, developing countries can enable themselves to build toward
self-sufficient blood management services and increased independence from the support of international
organizations. (J Patient Cent Res Rev. 2021;8:121-126.)
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T

ransfusion of blood and blood products is not only
critical in life-threatening emergencies but also
facilitates management of subacute and chronic
conditions in routine patient care.1 In developing
countries (DCs), such as those in sub-Saharan Africa,
the greatest need for transfusions is cited in children
with malaria-related anemia and women with obstetric
hemorrhage.1,2 These clinical scenarios are associated
with a mortality index of up to 25.5%.2 Although the
World Health Organization (WHO) included freshfrozen plasma, platelets, red blood cells, and whole
blood on its Model List of Essential Medicines in 2019,
many DCs lack reliable access to these products.3
Adequate blood product management requires a stable
supply, a standardized procedure for processing and
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testing, and appropriate clinical and laboratory skills for
use of products.1 The problem faced by most DCs can
be broken down into three basic components: insufficient
supply, excess demand, and inadequate quality of
available supply. This problem is further complicated
by the issue of cost. It has been shown that international
organizations such as the Red Cross cannot permanently
fund blood transfusion systems and that this responsibility
belongs to national authorities.4 In sub-Saharan Africa
many countries have utilized external funding to establish
national blood management services, but few have been
able to convert to reliable self-sufficient systems.1
Herein, we provide a narrative review of published
reports on the blood quantity, quality, and demand issues
many DCs encounter along with potential strategies for
advancing self-sufficient blood management services and
independence from international support.
Understanding the Problem

Compared to developed countries, DCs lack the voluntary
nonremunerated blood donors that are essential to
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maintaining adequate supply.5 Voluntary nonremunerated
donors are individuals who give blood products by their
own free will without receiving payment in return, be it
cash or any other substitute for money.4 These donors
are eligible to receive refreshments or small tokens of
low cash value for their donations. Remunerated donors
are those who do receive payment for their donations,
whereas replacement donors are individuals who elect to
donate blood products for direct transfusion to their family
and friends, usually on a one-time-only basis.4 Due to a
combination of infection-related apprehension and local
and cultural beliefs, DCs rely heavily on remunerated
donations.5,6 As a result, proportions of repeat donors are
low, resulting in an unstable supply of blood and a severe
lack of plasma derivatives, since very few DCs have the
fractionation plants required for their production.5

The delicate interplay between quantity and quality of
supply is exemplified by malaria, a leading cause of
anemia requiring transfusion in Africa that also can be
transmitted by transfusion.1 Despite the morbidity and
mortality associated with malaria, excluding donors
with low-grade parasitemia in endemic areas has the
potential to significantly reduce supply of available
blood.1 Of note, it is equally important for DCs to
ensure quality of blood products by pairing donors
and recipients using appropriate blood groupings and
crossmatching techniques.5 Infection by bacterial
components secondary to blood bank contamination
and breakdown of the cold chain, often due to frequent
power cuts during transport, are factors that are
frequently overlooked yet have significant capacity to
decrease quality of available supply.1

The shortage of donors in DCs is compounded by
nonindicated transfusion and a large volume of discarded
blood.5 Blood should be transfused only when clinically
appropriate. Unfortunately, most clinical transfusion
guidelines rely on formal assessments like qualityassured hemoglobin measurements.1 In places where
these services are unavailable, clinicians rely solely on
clinical judgment which, when faulty, can result in the
transfusion of a unit of blood that costs 40 times more
than a single accurate hemoglobin test.1 Despite the fact
that the majority of transfusion-related research has
focused heavily on preventing transfusion-transmitted
infections rather than addressing blood shortage, the
scope for increasing supply by reducing unnecessary
transfusion is likely substantial.1

Current Recommendations and Progress

Quality of available blood products in DCs has benefited
substantially from increased awareness of HIV, but efforts
to improve testing for other transfusion-transmissible
infectious agents are still warranted.5 Recent data have
shown that transfusion-associated infection rates in subSaharan Africa remain astronomically higher than those
in high-income countries, with risk of HIV, hepatitis B,
and hepatitis C transmission reaching 1, 4.3, and 2.5
infections per 1000 units of blood, respectively.7 In highincome countries, these rates are approximated to be 1 in
2 million, 1 in 100,000, and 1 in 2.5 million, respectively.7
Unfortunately, these infection rates likely underestimate
true transmission of disease because acquired viruses
can be passed on via a wave of secondary infections.1
As of 2016, antibody to the hepatitis C virus is not part
of routine blood screening in many parts of Africa, and
only a small proportion of blood banks use enzymelinked immunosorbent assay (ELISA) kits for hepatitis
B surface antigen because testing is not considered costeffective given the endemic nature of the virus.1
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The approaches typically used to secure an adequate
supply of high-quality blood in high-income countries
are not necessarily appropriate, validated, or practical
for implementation in DCs.8 In DCs, realistic solutions
must encourage reliance on local resources, establish
networks for research and education, and promote use of
guidelines and audits for gradual improvement of clinical
practice.1 In many countries where inadequate supply and
lack of funding are significant obstacles, progress can be
made by reorganizing existing systems.4 First, transfusion
medicine should be integrated into the national health
care system.1,4 This branch of medicine encompasses all
of the aspects of transfusion of blood products, including
but not limited to donor recruitment and retention,
collection, quality assessment, processing, storage, and
administration.4 Second, a national blood policy must
be created to define the organization(s) responsible
for providing blood services, means of funding these
services, acceptable forms of donation, and regulations
for conducting procurement and transfusion.4
Unfortunately, while nearly all African states had
established a national blood policy as of 2016, more
than half were unable to implement their policies.1
In many cases, inability to carry out a national blood
policy stems from a system of organization that relies
on the ability of hospitals to run their own blood
services without national control or coordination.4 The
International Foundation of Patient Blood Management
structures the development of a successful patient
blood management (PBM) program around the idea of
“giving the right blood products in the right amount to
the right patient at the right time.”9 It provides formal
recommendations for transparent transfusion guidelines,
appropriate education and training for clinical staff, and
feedback mechanisms for evaluating appropriateness of
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transfusion. Using this framework, countries like Uganda
have been able to develop PBM programs featuring
national oversight committees and standard operating
procedures within individual hospitals. Currently, most
sub-Saharan countries, including Uganda, are in the early
stages of developing PBM programs.9
Bolstering Supply

It has been reported that despite organized humanitarian
efforts, up to 80% of the world population currently
has access to only 20% of the world’s blood products.10
Unfortunately, the best way to bolster supply is to
encourage repeat donation by nonremunerated, voluntary
donors who were demonstrated, in a study of 2880 units of
blood in Egypt, to have significantly better health profiles
than remunerated donors.11 While it is difficult to stimulate
donor motivation, entities like the Federal Ministry of
Health in Nigeria have seen success by engaging the media
and televising donations by public figures.1 Nigeria also has
implemented strategies like Club 25 to recognize donors
under the age of 25 years, while Zimbabwe created the
Pledge 25 Club, a program that uses education incentives
to attract students to give blood 25 times.1 In India, issues
related to access resulting from a dispersed population
were addressed by the institution of a system of “walking
blood banks,” which consists of a pool of preapproved
healthy donors who can be recruited by rural hospitals to
provide a reliable and timely supply of blood.12,13
Educational programs and materials created by the
Red Cross and WHO have proved helpful in dispelling
apprehensions and false beliefs about the process of
blood donation, especially in rural areas.1,5 It is likely
that the most effective approaches for recruiting new
donors and converting remunerated donors to repeat
donors will involve the combined efforts of local and
international organizations. While it is promising that
global organizations have aimed to educate potential
donors and to circulate resources, it is essential that
these groups collaborate with local organizations.1 In
many ways, the task of finding donors may be more
reasonably assigned to the nonmedical community, such
as municipalities, schools, and religious organizations,
rather than to medical professionals. At its core, blood
product management is a public health issue, not a strictly
medical issue. The recruitment of new donors should fall
in the realm of public health authorities, partnered with
these nonmedical organizations, with the ultimate goal
being to change public opinion about donation.
Decreasing Demand

A systems approach to blood product management must
reflect a balance of bolstering and conserving supply as
well as decreasing demand. A significant proportion of the
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blood requirement in DCs is dedicated to the treatment of
anemia, especially in children. The prevalence of anemia
in South Africa is estimated to be 17% in males and 31%
in females compared to 3.5% and 7.6%, respectively, in the
United States.14,15 While many cases of anemia in DCs do
require treatment, demand can be managed by considering
alternative interventions such as use of haematinics for
the treatment of nutritional anemia and stimulation of
erythropoiesis prior to resorting to transfusion.5,14 Similarly,
treatment with hydroxyurea can be used to decrease
transfusion requirements in sickle cell anemia, and
high-hematocrit placental blood can be useful for smallvolume emergency transfusion in cases of neonatal
anemia.1 Novel strategies have been developed to reduce
excessive rates of exchange transfusions in infantile
hyperbilirubinemia.16,17 It is proposed that formally
assessing both total serum bilirubin and clinical signs
of encephalopathy allows for more accurate prediction
of kernicterus risk, helping to reduce transfusion
requirements and improve overall health outcomes.17
In cases of trauma associated with significant blood
loss, investigations like the Clinical Randomisation
of Antifibrinolytics Hemorrhage-2 (CRASH-2) study
demonstrated that tranexamic acid, an antifibrinolytic,
reduces all-cause mortality by 10% when administrated
within 3 hours of the initial trauma.1 Per PBM
recommendations, minimizing blood loss through
anesthetic and surgical techniques as well as optimizing
coagulation status before and during procedures is essential
to reducing blood requirements in both emergency and
scheduled operations.14 Educating transfusion prescribers
about appropriate protocols and available alternatives,
such as saline and colloids, also may help decrease
demand.5 Given that strict enforcement of a transfusion
protocol in a Malawian hospital reduced transfusion
numbers by 75%, it is possible that implementation of
these innovative interventions in conjunction with strict
transfusion guidelines may help significantly decrease
demand for blood and blood products in DCs without
negatively impacting mortality.1 It is vital to note,
however, that in any scenario the enforcement of protocols
is as important as their creation, since protocols tend to
fade away without adequate means for their enforcement.
Going hand in hand with the use of alternative therapies
and approaches as a means to decrease demand is
targeted reduction of waste. Some surgical procedures
are associated with an inherent risk of blood loss and
typically require preemptive crossmatching of blood, but
this blood is often wasted (at a cost of approximately $40
per unit).18 A study out of Pakistan recommended that
crossmatching be performed only if audits suggest that
there is a greater than 50% likelihood that the unit will
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be used.18 This practice, along with the general practice
of auditing usage of blood supply, is likely to promote
better stewardship of available products.
Improving Quality

HIV antibody, are under development for other infectious
agents.1 Successful development of these tests has the
potential to cut costs by decreasing the need for highly
skilled staff and advanced processing equipment.1

The effective supply of blood products is further hampered
by poor quality of those products that are available.2,5
Lack of adequate resources predisposes some countries
to continuously fall short of meeting set standards for
screening of transfusion-transmissible infection; in many
instances, communities within these countries are acutely
aware of this shortcoming, and individuals take this
information into account when choosing for or against
voluntary donation.19 As a result, distrust of health
systems is one of the key problems that lie at the heart of
the issues surrounding blood product management.

Alternatively, researchers are considering the option of
prophylactically treating recipients of red blood cells
in endemic regions with antimalarial agents instead of
excluding donors with low-grade parasitemia.1 Pathogen
reduction refers to a series of interventions that involve
using heat or alcohol fractionation to eliminate viral
components from plasma products. Pathogen reduction is
promising but cannot be used for whole blood or packed
red blood cells and is associated with logistic concerns,
including cost and requirements for complex equipment
and skilled personnel.19

There are two main strategies for improving quality of
available blood and blood products: predonation testing
and postdonation pathogen reduction. Recommendations
for blood product monitoring include testing for direct
antiglobulin and screening all donations for HIV,
hepatitis B virus, hepatitis C virus, syphilis, and regional
pathogens like arboviruses, Trypanosoma cruzi, and
human T-lymphotropic virus.1,5,20 Unfortunately, the
specificity, sensitivity, ease of use, and costs associated
with anti-HIV, anti-hepatitis C, and hepatitis B surface
antigen testing vary.1 For instance, widespread use of
nucleic acid testing is limited in most DCs by cost.1,11
Fortunately, more cost-effective substitutes for nucleic
acid testing, such as the use of two anti-HIV ELISA tests
performed in parallel, are being investigated.1 Similarly,
data out of Egypt suggest that core antigen testing is more
effective than RNA testing for determining the presence
of hepatitis C without sacrificing specificity.20 Rapid
immunochemical tests, such as those developed for the

It is important to note that as long as the prevalence of these
viruses remains high, residual risk of transmission will
not decrease even in the setting of adequate testing given
the existence of the window period.1 While it is essential
to channel efforts into developing adequate screening
protocols, it is equally if not more vital to address the
availability of antiretroviral therapy. Thus, poor quality
of available blood products can serve as a motivating
factor for both tighter usage guidelines and compliance
enforcement. This approach provides a simultaneous
solution to two important issues by helping to reduce
transmission of infection and by improving quantity and
quality of available supply for true emergency use.
Looking Forward

Uganda and other sub-Saharan countries that have taken
steps toward developing PBM programs serve as examples
of the implementation of novel, practical strategies for
blood delivery in lower-resource settings (Table 1). Of

Table 1. Strategies for a Three-Pronged Approach to Blood Product Management
Bolstering supply
• Engage the media, televise donations by public figures
• Target youth audiences using education initiatives
• Create “walking blood banks” to serve as a supply of blood for rural hospitals
Decreasing demand
• Consider alternative interventions (ie, hydroxyurea, stimulation of erythropoiesis, tranexamic acid)
• Improve education for use of fluids for resuscitation (ie, saline, colloids)
• Enforce strict transfusion protocol
• Reduce waste by limiting preemptive crossmatching
Improving quality
• Screen all donations for HIV, hepatitis B, hepatitis C, syphilis, and regional pathogens
• Consider alternative cost-effective techniques for predonation testing
• Implement prophylactic treatment of recipients for endemic diseases
• Increase availability of antiviral therapy to decrease transmission risk
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note, these approaches are often quite different than
those strategies utilized in higher-resource areas where
the majority of health care leaders are trained. The
challenges faced by health systems across the income
spectrum vary significantly, and it has become evident
that DCs must forge blood programs that complement
not only their health care infrastructure but also the
culture of their communities.21 When the literature
and public media highlight the shortcomings of blood
product management programs in low- and middleincome countries by comparing them directly to
wealthier nations, they often overlook the nuances that
require these delivery programs to be innately different.22
While beyond the scope of this review, a more beneficial
approach may be to shed light on novel strategies used
by lower-resource health systems such that others may
use these examples as a starting point to addressing
shortcomings of their own programs.
Summary

Problems associated with transfusion of blood and blood
products in developing countries stem from insufficient
supply, excessive demand, and inadequate quality of
available supply. While initiatives of international
organizations have bolstered blood transfusion systems
in DCs across the world, progressive improvement of
these systems is greatly needed. DCs should focus on
increasing repeat volunteer donor rates through enriched
education materials, advancing testing techniques to
audit the quality of available blood, and improving
medical management of subacute and chronic conditions
that would otherwise require transfusion. International
organizations can aid DCs in the pursuit of these goals
by addressing barriers like access to resources and cost.
These efforts, however, should be supportive rather than
enabling, since the long-term success of any independent
blood transfusion system is determined by the ability of
national authorities to maintain it over time.
Patient-Friendly Recap
•D
 eveloping countries can face considerable
obstacles to making high-quality blood, platelets,
plasma, and other blood products available to
patients in need of transfusion.
• The authors reviewed three approaches to bettering
blood management in these countries — bolstering
supply, decreasing demand, and improving quality.
•S
 trategies described in this review may enable
developing countries to build more efficient and
self-sufficient blood management systems that are
less dependent on support from international health
organizations.
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